Drug Repurposing
Fifty 1 Labs Engages PCAOB Auditor in Strategic Move Toward OTCQB Uplist
Fifty 1 Labs has taken a significant step toward uplisting to the OTCQB Venture Market by engaging a PCAOB-registered auditor, signaling enhanced corporate governance and transparency for the AI-driven drug repurposing company.
Fifty 1 Labs Subsidiary Partners with LUNR Aerospace to Develop AI-Driven Space Medicine Solutions
Fifty 1 Labs' subsidiary has partnered with LUNR Aerospace to develop AI-driven drug repurposing for space medicine, positioning the company to capitalize on the rapidly growing $1.97 billion space medicine market while creating dual-use opportunities across multiple industries.
Fifty 1 Labs Partners with Stanford Initiative on AI-Driven Pandemic Preparedness
Fifty 1 Labs collaborates with ViRx@Stanford to use artificial intelligence for rapid drug repurposing against emerging viral threats, aiming to strengthen global health security and reduce future pandemic mortality risks.
Fifty 1 Labs and BioSpark AI Pioneer AI-Driven Drug Repurposing with Major Database Achievement
Fifty 1 Labs and BioSpark AI have created a structured database from over 10,000 case reports, marking a significant advancement in AI-driven drug repurposing for complex conditions.
Fifty 1 Labs to Host Virtual Shareholder Teleconference Featuring Nobel Laureate Dr. James Orbinski
Fifty 1 Labs announces a virtual shareholder teleconference to discuss its strategic roadmap, including AI-driven drug repurposing and significant R&D investments, highlighting its commitment to innovation in health and wellness.
Fifty 1 Labs and UAV Corp Announce Strategic Partnership to Acquire BioSpark AI for Drug Repurposing Advancements
Fifty 1 Labs, Inc. and UAV Corp have announced a strategic partnership and intent to acquire BioSpark AI Technologies Inc., aiming to revolutionize drug repurposing through AI and large language model technologies.
Fifty 1 Labs and UAV Corp Unveil AI-Driven Strategy for NASDAQ Uplisting
Fifty 1 Labs, Inc. and UAV Corp announce a strategic plan to achieve a $50 million valuation and uplist to NASDAQ, leveraging AI in drug repurposing and functional medicine.